Background: The TCGA molecular groups of endometrial carcinoma are “POLE-mutated” (POLEmut), “microsatellite-instable/mismatch repair-deficient” (MSI/MMRd), “TP53-mutated/p53-abnormal” (TP53mut/p53abn), and “no specific molecular profile” (NSMP). Objective: Prognostic assessment of the TCGA groups in uterine carcinosarcoma (UCS). Search strategy: Systematic review from January 2000 to January 2021. Selection criteria: Studies assessing the TCGA groups in UCS. Data collection and analysis: Progression-free survival (PFS) and overall survival (OS) were assessed by Kaplan–Meier and Cox analyses (reference: TP53mut/p53abn group) and compared with endometrioid and serous carcinomas (original TCGA cohort), with a significant P < 0.050. Main results: Five studies with 263 UCS were included. Compared with TP53mut/p53abn UCS, MSI/MMRd UCS showed significantly better PFS (P < 0.001) but similar OS (P = 0.788), whereas NSMP UCS showed similar PFS (P = 0.936) and OS (P = 0.240). Compared with their endometrioid/serous counterparts, NSMP and TP53mut/p53abn UCS showed significantly worse PFS (P < 0.001 and P = 0.004) and OS (P < 0.001 and P < 0.001), while MSI/MMRd UCS showed similar PFS (P = 0.595) but significantly worse OS (P < 0.001). The POLEmut group showed neither recurrences nor deaths in both the UCS and the endometrioid/serous carcinoma cohorts. Conclusion: POLEmut UCS show excellent prognosis, whereas TP53mut/p53abn and NSMP UCS show a prognosis even worse than that of TP53mut/p53abn endometrioid/serous carcinomas. The prognosis of MSI/MMRd UCS remains to be defined.

Travaglino, A., Raffone, A., Raimondo, D., Arciuolo, D., Angelico, G., Valente, M., Scaglione, G., D'Alessandris, N., Casadio, P., Inzani, F., Mollo, A., Santoro, A., Seracchioli, R., Zannoni, G. F., Prognostic value of the TCGA molecular classification in uterine carcinosarcoma, <<INTERNATIONAL JOURNAL OF GYNAECOLOGY AND OBSTETRICS>>, 2022; 158 (1): 13-20. [doi:10.1002/ijgo.13937] [https://hdl.handle.net/10807/304075]

Prognostic value of the TCGA molecular classification in uterine carcinosarcoma

Arciuolo, Damiano;Valente, Michele;Scaglione, Giulia;D'Alessandris, Nicoletta;Inzani, Frediano;Santoro, Angela;Zannoni, Gian Franco
2022

Abstract

Background: The TCGA molecular groups of endometrial carcinoma are “POLE-mutated” (POLEmut), “microsatellite-instable/mismatch repair-deficient” (MSI/MMRd), “TP53-mutated/p53-abnormal” (TP53mut/p53abn), and “no specific molecular profile” (NSMP). Objective: Prognostic assessment of the TCGA groups in uterine carcinosarcoma (UCS). Search strategy: Systematic review from January 2000 to January 2021. Selection criteria: Studies assessing the TCGA groups in UCS. Data collection and analysis: Progression-free survival (PFS) and overall survival (OS) were assessed by Kaplan–Meier and Cox analyses (reference: TP53mut/p53abn group) and compared with endometrioid and serous carcinomas (original TCGA cohort), with a significant P < 0.050. Main results: Five studies with 263 UCS were included. Compared with TP53mut/p53abn UCS, MSI/MMRd UCS showed significantly better PFS (P < 0.001) but similar OS (P = 0.788), whereas NSMP UCS showed similar PFS (P = 0.936) and OS (P = 0.240). Compared with their endometrioid/serous counterparts, NSMP and TP53mut/p53abn UCS showed significantly worse PFS (P < 0.001 and P = 0.004) and OS (P < 0.001 and P < 0.001), while MSI/MMRd UCS showed similar PFS (P = 0.595) but significantly worse OS (P < 0.001). The POLEmut group showed neither recurrences nor deaths in both the UCS and the endometrioid/serous carcinoma cohorts. Conclusion: POLEmut UCS show excellent prognosis, whereas TP53mut/p53abn and NSMP UCS show a prognosis even worse than that of TP53mut/p53abn endometrioid/serous carcinomas. The prognosis of MSI/MMRd UCS remains to be defined.
2022
Inglese
Travaglino, A., Raffone, A., Raimondo, D., Arciuolo, D., Angelico, G., Valente, M., Scaglione, G., D'Alessandris, N., Casadio, P., Inzani, F., Mollo, A., Santoro, A., Seracchioli, R., Zannoni, G. F., Prognostic value of the TCGA molecular classification in uterine carcinosarcoma, <<INTERNATIONAL JOURNAL OF GYNAECOLOGY AND OBSTETRICS>>, 2022; 158 (1): 13-20. [doi:10.1002/ijgo.13937] [https://hdl.handle.net/10807/304075]
File in questo prodotto:
File Dimensione Formato  
Intl J Gynecology Obste - 2021 - Travaglino - Prognostic value of the TCGA molecular classification in uterine.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.38 MB
Formato Adobe PDF
1.38 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/304075
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 29
social impact